Title

Cardiovascular Health Status of Childhood Cancer Survivors Treated With Anthracyclines

Presenter

Morrow Toomey

Abstract

Anthracycline-based anticancer drugs pose a unique challenge to researchers seeking to improve long-term health outcomes in pediatric cancer patients as these drugs are associated with superior treatment outcomes, as well as late-cardiotoxic events. In adult cancer patients, the cardioprotectant dexrazoxane (DRZ) has been shown to mitigate associated cardiotoxicity when given in conjunction with anthracycline-based agents. In children, studies of the efficacy of dexrazoxane have been more limited. In order to better understand the effects of DRZ, individuals who were treated from 1996-2001 on Children’s Oncology Group DRZ randomized clinical trials were approached for prospective health assessment at sites across North America. Eligible survivors were assessed on anthropometry, six-minute walk distance, and self-reported physical activity and smoking history. Our analysis compared these data across DRZ treatment arms and compared survivors to an age-matched general population sample to give a preliminary cardiovascular health update on childhood cancer survivors treated with anthracyclines.

Faculty Sponsor

James Russo

Sponsor Department/Programs

Anthropology

Tracks

Poster Session

Location

Cordiner Hall

Presentation Type

Poster

Research Funding Source or OCS Program

the Whitman-FHCRC Summer Internship Fund, the Cancer Center Support Grant CURE Supplement, the FHCRC?€?s Internship Program, and individual FHCRC groups

This document is currently not available here.

Share

COinS
 
Apr 19th, 1:00 PM Apr 19th, 2:00 PM

Cardiovascular Health Status of Childhood Cancer Survivors Treated With Anthracyclines

Cordiner Hall

Anthracycline-based anticancer drugs pose a unique challenge to researchers seeking to improve long-term health outcomes in pediatric cancer patients as these drugs are associated with superior treatment outcomes, as well as late-cardiotoxic events. In adult cancer patients, the cardioprotectant dexrazoxane (DRZ) has been shown to mitigate associated cardiotoxicity when given in conjunction with anthracycline-based agents. In children, studies of the efficacy of dexrazoxane have been more limited. In order to better understand the effects of DRZ, individuals who were treated from 1996-2001 on Children’s Oncology Group DRZ randomized clinical trials were approached for prospective health assessment at sites across North America. Eligible survivors were assessed on anthropometry, six-minute walk distance, and self-reported physical activity and smoking history. Our analysis compared these data across DRZ treatment arms and compared survivors to an age-matched general population sample to give a preliminary cardiovascular health update on childhood cancer survivors treated with anthracyclines.